Literature DB >> 19900166

Hypoxia and non-alcoholic fatty liver disease.

Christopher D Byrne1.   

Abstract

NAFLD (non-alcoholic fatty liver disease) represents a spectrum of fatty liver diseases associated with an increased risk of Type 2 diabetes and cardiovascular disease. The spectrum of fatty liver diseases comprises simple steatosis, steatosis with inflammation [i.e. NASH (non-alcoholic steatohepatitis)], fatty liver disease with inflammation and fibrosis (severe NASH) and cirrhosis. The molecular mechanisms contributing to NASH are the subject of considerable investigation, as a better understanding of the pathogenesis of NASH will lead to novel therapies for a condition that hitherto remains difficult to treat. In the present issue of Clinical Science, Piguet and co-workers have investigated the effects of hypoxia in the PTEN (phosphatase and tensin homologue deleted on chromosome 10)-deficient mouse, a mouse model that develops NAFLD. The authors show that a short period (7 days) of exposure to hypoxia aggravates the NAFLD phenotype, causing changes in the liver that are in keeping with NASH with increased lipogenesis and inflammation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19900166     DOI: 10.1042/CS20090565

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  12 in total

1.  Selection of reference genes for qRT-PCR in high fat diet-induced hepatic steatosis mice model.

Authors:  Lingyan Xu; Xinran Ma; Bin Cui; Xiaoying Li; Guang Ning; Shu Wang
Journal:  Mol Biotechnol       Date:  2011-07       Impact factor: 2.695

2.  Hepatocellular carcinoma is accelerated by NASH involving M2 macrophage polarization mediated by hif-1αinduced IL-10.

Authors:  Aditya Ambade; Abhishek Satishchandran; Banishree Saha; Benedek Gyongyosi; Patrick Lowe; Karen Kodys; Donna Catalano; Gyongyi Szabo
Journal:  Oncoimmunology       Date:  2016-09-26       Impact factor: 8.110

Review 3.  Obstructive sleep apnea syndrome and fatty liver: association or causal link?

Authors:  Mohamed-H Ahmed; Christopher-D Byrne
Journal:  World J Gastroenterol       Date:  2010-09-14       Impact factor: 5.742

Review 4.  Systemic and renal lipids in kidney disease development and progression.

Authors:  Patricia Wahl; Gloria Michelle Ducasa; Alessia Fornoni
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-23

5.  Roles for PI3K/AKT/PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver Disease.

Authors:  Satoru Matsuda; Mayumi Kobayashi; Yasuko Kitagishi
Journal:  ISRN Endocrinol       Date:  2013-01-30

Review 6.  Metabolism, energetics, and lipid biology in the podocyte - cellular cholesterol-mediated glomerular injury.

Authors:  Sandra Merscher; Christopher E Pedigo; Armando J Mendez
Journal:  Front Endocrinol (Lausanne)       Date:  2014-10-14       Impact factor: 5.555

7.  Protein inhibitor of activated STAT 4 (PIAS4) regulates liver fibrosis through modulating SMAD3 activity.

Authors:  Huihui Xu; Zhiwen Fan; Wenfang Tian; Yong Xu
Journal:  J Biomed Res       Date:  2016-08-01

Review 8.  Hypoxia in Obesity and Diabetes: Potential Therapeutic Effects of Hyperoxia and Nitrate.

Authors:  Reza Norouzirad; Pedro González-Muniesa; Asghar Ghasemi
Journal:  Oxid Med Cell Longev       Date:  2017-05-08       Impact factor: 6.543

Review 9.  Phosphatase and Tensin Homolog in Non-neoplastic Digestive Disease: More Than Just Tumor Suppressor.

Authors:  Tianyu He; Xiaoyun Zhang; Jianyu Hao; Shigang Ding
Journal:  Front Physiol       Date:  2021-06-01       Impact factor: 4.566

Review 10.  Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists?

Authors:  Mohamed H Ahmed; Salma Barakat; Ahmed O Almobarak
Journal:  J Obes       Date:  2012-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.